research Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
Search
for
Sort by
Research
30 / 1000+ results 
research Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
research Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
research Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
research Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
research Teriflunomide in multiple sclerosis: an update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
research “Nail loss after teriflunomide treatment: A new potential adverse event”
Nail loss may be a side effect of the MS drug teriflunomide.
research Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?
Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.
research Hair Loss Associated with Teriflunomide Treatment
Teriflunomide can cause hair thinning.
research Teriflunomida and hair disorders
Teriflunomide often causes mild to moderate hair thinning and loss in MS patients, which usually improves with or without treatment.
research Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
research Tether-induced tenosynovitis: The importance of an intact skin barrier
An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
research Leflunomide
Leflunomide is effective for rheumatoid arthritis but has significant side effects.
research Leflunomide for the treatment of trichodysplasia spinulosa in a liver transplant recipient
Leflunomide successfully treated a rare skin condition in a liver transplant patient.
research An observational study of leflunomide in the treatment of lupus nephyritis for cyclophosphamide was invalid or could not be tolerated
Leflunomide with prednisone is effective and well-tolerated for lupus nephritis when cyclophosphamide can't be used.
research Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata
Leflunomide is more likely to help treat alopecia areata than cause it.
research Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis
Leflunomide and methotrexate are equally effective for rheumatoid arthritis but have different side effects.
research POS0080 TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE
Tofacitinib is a promising treatment for children with rheumatic diseases.
research 0282 Effect of systemic immunomodulators on incidence of alopecia areata: A retrospective cohort study
Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
research Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis
Leflunomide and methotrexate are similarly effective for rheumatoid arthritis but have different side effects.
research Effect of Systemic Immunomodulators on Incidence of Alopecia Areata: A Retrospective Cohort Study
Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.
research Alopecia areata secondary to the use of leflunomide in patients with rheumatoid arthritis: a case report and literature review
Leflunomide can cause severe hair loss in some rheumatoid arthritis patients.
research AB0987 ANIFROLUMAB TREATMENT IMPROVES QUALITY OF LIFE AND DECREASES SYSTEMIC CORTICOSTEROID USE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
research Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
research THE USE OF TOFACITINIB IN THE TREATMENT OF IMMUNE-MEDIATED UNIVERSAL ALOPECIA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT
Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
research THERAPEUTIC CHALLENGES IN POLYAUTOIMMUNITY: ANIFROLUMAB FOR LUPUS ERYTHEMATODES IN OVERLAPPING AUTOIMMUNE SYNDROMES
Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
research Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis
Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.
research Immunosuppressive treatment for proliferative lupus nephritis
Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.
research P0881 Effectiveness and Safety of Tofacitinib in Biologic-Naïve Elderly Patients with Ulcerative Colitis
Tofacitinib is effective and safe for elderly patients with ulcerative colitis.